BNTC (Benitec Biopharma) Moat Score: 3/10 (As of Jun. 27, 2026)


BNTC Benitec Biopharma Inc BNTC
34 GF Score
Price $12.35
View Full Analysis

What is Benitec Biopharma Moat Score?

Benitec Biopharma BNTC -4.77% 34 Moat Score is 3 as of Jun. 27, 2026. GuruFocus rates BNTC with a GF Score™ of 34/100. Among 1,404 Biotechnology companies, Benitec Biopharma ranks better than 75.5% on this metric.

Benitec Biopharma has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Benitec Biopharma has No Moat: Benitec Biopharma operates in a competitive biotech space with limited market leadership and lacks significant customer switching costs or strong brand loyalty. While it may have some intellectual property, it does not possess durable cost advantages or significant regulatory barriers.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Benitec Biopharma might have No Moat - Very weak/transient advantages.

Benitec Biopharma  (NAS:BNTC) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Benitec Biopharma Moat Score Related Terms

BNTC vs OABI, FBRX, LXEO: Moat Score Comparison

For the Biotechnology subindustry, Benitec Biopharma's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Benitec Biopharma Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Benitec Biopharma's Moat Score distribution charts can be found below:

* The bar in red indicates where Benitec Biopharma's Moat Score falls into.


BNTC
34GF Score
Benitec Biopharma Inc BNTC
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Benitec Biopharma (BNTC) has a Moat Score of 3 as of Jun. 27, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Benitec Biopharma ranks #344 out of 1404 companies in the Biotechnology industry, placing it in the top 24.5%.
Is Benitec Biopharma's Moat Score too high?
Benitec Biopharma's current Moat Score is 3. The Biotechnology industry median Moat Score is 2.00. Benitec Biopharma's value of 3 is 50% above this industry median. Based on the distribution chart, Benitec Biopharma ranks #344 out of 1404 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Benitec Biopharma has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Benitec Biopharma's Moat Score compare to OABI and FBRX?
According to the Biotechnology industry distribution chart, Benitec Biopharma ranks #344 out of 1404 companies for Moat Score. This places Benitec Biopharma in the top 25% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Benitec Biopharma's value of 3 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,404 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Benitec Biopharma's current Moat Score of 3 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Benitec Biopharma's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Benitec Biopharma stock overvalued right now?
Benitec Biopharma (BNTC) has a current Moat Score of 3. The current Moat Score is 3 and 50% above the Biotechnology industry median of 2.00. Benitec Biopharma's overall GF Score™ is 34/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Benitec Biopharma (BNTC), the current Moat Score is 3 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Benitec Biopharma Business Description

Address 3940 Trust Way, Hayward, CA, USA, 94545
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.
34GF Score

Get the complete analysis for BNTC

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.35
Price